Cholesterol and Lipid Profile on Steroid Cycle
Blood Work · 6 min read · Updated on May 23, 2026
The impact of steroids on the lipid profile is one of the most documented and most underestimated effects: felt at zero, visible on every blood panel. The medium- to long-term consequence is cardiovascular — and it is the single biggest item on the risk side of a multi-year cycling career, far more than the more visible fears (gyno, acne).
This guide explains how steroids — and especially 17-alpha-alkylated orals — wreck the lipid profile, which values to watch, and which levers actually buffer the impact. It belongs to the blood work on cycle cluster.
Why steroids wreck the lipid profile
Anabolic steroids increase hepatic lipase activity, the enzyme that breaks down HDL cholesterol (the 'good' cholesterol — the one that ferries excess cholesterol back to the liver). Result: HDL drops, sometimes drastically. In parallel, several compounds raise LDL (the 'bad' cholesterol). The LDL/HDL ratio, one of the best predictors of atherosclerotic cardiovascular risk, deteriorates in both directions at once [2].
The effect is much more pronounced under 17-alpha-alkylated orals (Winstrol, Anavar, Anadrol, Dianabol) because of their first-pass hepatic metabolism. Winstrol has a particularly bad reputation for HDL: drops of 50 to 70% in a few weeks are regularly reported in clinical practice for oral users [3].
Markers and their targets
| Marker | Adult male target | Reading on cycle |
|---|---|---|
| HDL | > 40 mg/dL (1.0 mmol/L) | Expected drop; under 30 mg/dL: alert |
| LDL | < 130 mg/dL (3.4 mmol/L) | Frequent rise, especially under orals |
| Total cholesterol | < 200 mg/dL (5.2 mmol/L) | Possible rise |
| Triglycerides | < 150 mg/dL (1.7 mmol/L) | Variable; possible drop under testosterone |
| Apolipoprotein B (apoB) | < 90 mg/dL | Marker of atherogenic particle count |
| Lp(a) | < 30 mg/dL | Genetic risk marker, measure once |
HDL: the most sensitive marker
If a single lipid marker has to be tracked rigorously on cycle, it is HDL: it drops the fastest and the deepest. A normal value (> 40 mg/dL in men) that falls toward 20 mg/dL in a few weeks under an oral is a major signal. Recovery after stopping the oral is usually partial in the following weeks and complete over a few months, but repeated protocols leave a cumulative footprint [1].
The compounds that wreck lipids most
- Stanozolol (Winstrol). Worst reputation on HDL — see the Winstrol page.
- Oxandrolone (Anavar). Often labeled 'tolerable', it still clearly degrades the lipid profile. See Anavar.
- Oxymetholone (Anadrol). One of the most marked lipid impacts, on top of its hepatotoxicity.
- Methandrostenolone (Dianabol). Clear LDL rise and HDL drop.
- Trenbolone. Heavy overall cardiovascular impact — HDL crash among the consequences.
Compounds relatively 'softer' on lipids
On the injectable side, testosterone-only at a contained dose (enanthate for example) has a more modest lipid impact than orals. Nandrolone and boldenone are also less aggressive on HDL than 17α-alkylated orals. That does not erase the effect, but it cuts it substantially [3] — one of the arguments in favor of 'all-injectable' cycles for users who want to limit their lipid footprint.
The management levers
1. Compound selection and duration
The first lever — and the most effective — sits upstream: limit orals (duration and stacking), favor injectables as the base, cap oral windows at 4 to 6 weeks max, and do not stack two 17α-alkylated orals. For anyone systematically pairing Anadrol + Dianabol or Winstrol + Anavar, the lipid profile is going to wreck itself, and omega-3 will not change much.
2. Omega-3
Omega-3 fatty acids (EPA + DHA) at a substantial dose — typically 2 to 4 g per day of combined EPA+DHA, from a quality source — are the most consistently cited supplement for buffering the lipid impact. The effect is real but partial: they are not enough to neutralize the impact of stacked orals at full dose [4].
3. Cardio
Regular cardiovascular activity (zone 2 for 150 to 200 min/week, plus a few harder sessions) raises HDL, lowers triglycerides and blood pressure, and improves endothelial health. It is one of the variables that, over the long run, separates cyclers who stay cardiovascularly healthy from those who drift.
4. Nutrition
- Keep a meaningful share of the diet on whole, unprocessed foods (vegetables, fruit, legumes, fatty fish).
- Limit very high saturated fat intake combined with orals.
- Moderate alcohol: it stacks on top of hepatic load from orals and worsens the lipid profile.
5. Statins: not self-prescribed
Some advanced users take statins (atorvastatin, rosuvastatin) on prescription to buffer the impact of cycles heavy in orals or prolonged blasts. This is a medical decision, not a DIY: statins have their own side effects (muscular, hepatic) that can stack with those of orals. Do not take them without a prescription.
When and how to monitor your lipid profile
- Baseline 2 to 4 weeks before the first injection: full lipid panel, ideally with apoB.
- Mid-cycle (week 4 to 8 depending on cycle length), especially if an oral is in play: lipid panel check. If the oral is capped at 4 to 6 weeks, take the draw in the last week of the oral.
- Post-PCT: lipid recovery panel 6 to 8 weeks after the complete stop of all compounds.
The lipid panel is drawn fasted (10 to 12 hours without calories, water OK) for triglyceride reliability in particular. AnaProtoKol's blood work feature imports the lab PDFs and plots each marker on its own curve, with the baseline as reference — the format that lets you read the trajectory and not just the point. For the global schedule, see blood test schedule for a cycle.
Frequently asked questions
How long does HDL take to recover after a cycle of orals?
HDL recovery after stopping 17α-alkylated orals is generally gradual over several weeks to a few months. A meaningful part returns in the 4 to 8 weeks after stopping, but the return to baseline values can take longer, especially after long or repeated cycles. Repeated protocols often leave a cumulative footprint: a user after several years of cycles can have a less favorable lipid baseline than at the start of their career.
Omega-3: which form and what dose?
Favor a quality source (fish oil in triglyceride or rTG form, or algae oil for vegetarians) with the EPA and DHA dose clearly stated — not just 'total omega-3'. The dose commonly cited in the cycling context is 2 to 4 g of combined EPA+DHA per day, taken with a meal. Cheap supplements of unclear quality will not deliver: it is the actual EPA+DHA total that matters, and quality (peroxides, contaminants) drives GI tolerance. Brands like Nordic Naturals, Carlson and Now's Ultra Omega-3 are commonly cited in the community.
Should I get a coronary calcium score on long cycles?
For users on cumulative cycles over years (blast and cruise, multi-year cycling career), the coronary calcium score is a non-invasive exam (low-dose CT) that measures calcified atheroma in the coronary arteries. It gives a direct picture of long-term cardiovascular drift — far more tangible than a lipid panel. Its relevance is discussed with a cardiologist typically from the fifth decade onward, or earlier if the lipid profile is heavily degraded. Not a routine cycle exam, but a useful tool in certain cycling paths.
Sources
Studies and scientific publications this guide relies on.
- Hartgens F, Rietjens G, Keizer HA, et al. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine. doi: 10.1136/bjsm.2003.000199
Étude prospective comparant deux régimes de stéroïdes anabolisants (oraux et injectables) : effets profondément défavorables sur HDL, apoA-I et apoB pendant l'administration, avec récupération partielle six semaines après l'arrêt ; le profil lipidique reste altéré après le sevrage.
- Sader MA, Griffiths KA, McCredie RJ, et al. (2001). Androgenic anabolic steroids and arterial structure and function in male bodybuilders. Journal of the American College of Cardiology. doi: 10.1016/s0735-1097(00)01083-4
Étude cas-témoin chez des bodybuilders : la consommation d'AAS s'accompagne d'une baisse significative du HDL-cholestérol par rapport aux bodybuilders non-utilisateurs et aux témoins sédentaires, sans différence d'épaisseur intima-média ou de fonction endothéliale dans cette cohorte transversale.
- Hartgens F, Kuipers H (2004). Effects of androgenic-anabolic steroids in athletes. Sports Medicine. doi: 10.2165/00007256-200434080-00003
Revue systématique : chute du HDL pouvant atteindre 40 à 70 % sous oraux 17α-alkylés (Winstrol notamment), montée du LDL, dégradation du rapport LDL/HDL — effet plus marqué que sous injectables non-alkylés.
- Smit DL, Grefhorst A, Buijs MM, et al. (2022). Prospective study on blood pressure, lipid metabolism and erythrocytosis during and after androgen abuse. Andrologia. doi: 10.1111/and.14372
Étude prospective HAARLEM : dégradation parallèle du HDL, du LDL et de l'apoB pendant le cycle, normalisation lente à 12 mois post-arrêt — la réversibilité du profil lipidique est partielle et lente.
- Baggish AL, Weiner RB, Kanayama G, et al. (2017). Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. doi: 10.1161/CIRCULATIONAHA.116.026945
Étude transversale chez 86 utilisateurs d'AAS au long cours : volume coronaire calcifié augmenté, athérosclérose coronaire accélérée, profil lipidique fortement dégradé — chaînon entre l'effet lipidique aigu sous cure et le risque cardiovasculaire à long terme.
Guides liés
Track your cycle with real data
Daily journal, 52 compounds, blood work and AI analysis — to apply what you just read and track results cycle after cycle.
Free 5-day trial — no credit card